Lloyd-PuryearMATonnigesTVan DyckPCMannMYBrinAJohnsonKAmerican Academy of Pediatrics Newborn Screening Task Force recommendations: how far have we come?Pediatrics2006; 117(5 Pt 2):S194–211.
4.
TherrellBLAdamsJ. Newborn screening in North America. J Inherit Metab Dis2007; 30:447–65.
5.
MacCreadyRAHusseyMG. Newborn phenylketonuria detection in Massachusetts. Am J Public Health Nations Health1964; 54:2075–81.
6.
GuthrieRSusiA. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics1963; 32:338–43.
7.
Van Dyck PC, Edwards ES. A look at newborn screening: today and tomorrow. Pediatrics2006; 117(5 Pt 2):S193.
8.
National Research Council. Genetic screening: programs, principles, and research. Washington: National Academy of Sciences; 1975.
9.
Serving the family from birth to the medical home. Newborn screening: a blueprint for the future—a call for a national agenda on state newborn screening programs. Pediatrics2000; 106(2 Pt 2):389–422.
10.
Newborn screening: toward a uniform panel and system. Genet Med2006; 8Suppl 1:1S–252S.
11.
TherrellBLHannonWH. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev2006; 12:236–45.
PerrinJMKnappAABrowningMFComeauAMGreenNSLipsteinEAAn evidence development process for newborn screening. Genet Med2010; 12:131–4.
14.
ChaceDHKalasTANaylorEW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem2003; 49:1797–817.
15.
MillingtonDSKodoNNorwoodDLRoeCR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis1990; 13:321–4.
16.
Centers for Disease Control and Prevention (US). Newborn Screening Quality Assurance Program [cited 2013 Feb 22]. Available from: URL: http://www.cdc.gov/labstandards/nsqap.html
17.
McCabeERHuangSZSeltzerWKLawML. DNA microextraction from dried blood spots on filter paper blotters: potential application for newborn screening. Hum Genet1987; 75:213–6.
18.
ZhangYHMcCabeLLWilbornMTherrellBLJrMcCabeER. Application of molecular genetics in public health: improved follow-up in a neonatal hemoglobinopathy screening program. Biochem Med Metab Biol1994; 52:27–35.
19.
ClarkeGMHigginsTN. Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clin Chem2000; 46(8 Pt 2):1284–90.
20.
BakerMWGrossmanWJLaessigRHHoffmanJLBrokoppCDKurtyczDFDevelopment of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol2009; 124:522–7.
21.
BakerMWLaessigRHKatcherMLRoutesJMGrossmanWJVerbskyJImplementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep2010; 125(Suppl 2):88–95.
MillingtonDSSistaREckhardtARouseJBaliDGoldbergRDigital microfluidics: a future technology in the newborn screening laboratory?Semin Perinatol2010; 34:163–9.
24.
Eunice Kennedy Shriver National Institute of Child Health and Human Development National Human Genome Research Institute. Genomic sequencing and newborn screening disorders (U19) [cited 2013 Feb 22]. Available from: URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-13-010.html
Therrell BL Jr. Ethical, legal, and social issues in newborn screening in the United States. Southeast Asian J Trop Med Public Health2003;34Suppl 3:52–8.
27.
LewisMHGoldenbergAAndersonRRothwellEBotkinJ. State laws regarding the retention and use of residual newborn screening blood specimens. Pediatrics2011; 127:703–12.
28.
Health Resources and Services Administration (US). Baby's first test: how screening works [cited 2013 Feb 22]. Available from: URL: http://www.babysfirsttest.org
TherrellBLHannonWHBaileyDBJrGoldmanEBMonacoJNorgaard-PedersenBCommittee report: considerations and recommendations for national guidance regarding the retention and use of residual dried blood spot specimens after newborn screening. Genet Med2011; 13:621–4.